JP2023549533A - 眼の状態を処置するための薬理剤 - Google Patents

眼の状態を処置するための薬理剤 Download PDF

Info

Publication number
JP2023549533A
JP2023549533A JP2023528761A JP2023528761A JP2023549533A JP 2023549533 A JP2023549533 A JP 2023549533A JP 2023528761 A JP2023528761 A JP 2023528761A JP 2023528761 A JP2023528761 A JP 2023528761A JP 2023549533 A JP2023549533 A JP 2023549533A
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
cycloalkyl
halo
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549533A5 (https=
Inventor
シンハ,サントシュ・シー
プラサド,スリドハー・ゴビンダ
ピーターマン,マーシャル・シー
Original Assignee
プレックス ファーマスーティカルズ,インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレックス ファーマスーティカルズ,インク filed Critical プレックス ファーマスーティカルズ,インク
Publication of JP2023549533A publication Critical patent/JP2023549533A/ja
Publication of JP2023549533A5 publication Critical patent/JP2023549533A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/45Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/12Esters of phosphoric acids with hydroxyaryl compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023528761A 2020-11-13 2021-11-15 眼の状態を処置するための薬理剤 Pending JP2023549533A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063113691P 2020-11-13 2020-11-13
US63/113,691 2020-11-13
US202163215818P 2021-06-28 2021-06-28
US63/215,818 2021-06-28
PCT/US2021/072405 WO2022104383A1 (en) 2020-11-13 2021-11-15 Pharmacological agents for treating conditions of the eye

Publications (2)

Publication Number Publication Date
JP2023549533A true JP2023549533A (ja) 2023-11-27
JP2023549533A5 JP2023549533A5 (https=) 2024-11-25

Family

ID=81601792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528761A Pending JP2023549533A (ja) 2020-11-13 2021-11-15 眼の状態を処置するための薬理剤

Country Status (6)

Country Link
US (1) US20240000812A1 (https=)
EP (1) EP4243798A4 (https=)
JP (1) JP2023549533A (https=)
CA (1) CA3202073A1 (https=)
MX (1) MX2023005675A (https=)
WO (1) WO2022104383A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11872236B2 (en) 2018-04-05 2024-01-16 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
WO2025090994A1 (en) * 2023-10-26 2025-05-01 Plex Pharmaceuticals, Inc. Compositions for treating cataracts and/or presbyopia eye diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095257A2 (en) * 2013-12-18 2015-06-25 Emory University Managing visual dysfunction or loss of vision for diabetic subjects
WO2019195761A2 (en) * 2018-04-05 2019-10-10 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329161T3 (es) * 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
RU2747536C2 (ru) * 2011-10-24 2021-05-06 Сом Инновэйшн Биотек, С.Л. Новая терапия транстиретин-ассоциированного амилоидоза
CA2860022A1 (fr) * 2011-12-30 2013-07-04 Universite D'auvergne Clermont I Composes anti-douleur
WO2014164667A1 (en) * 2013-03-11 2014-10-09 Georgetown University Dengue and west nile virus protease inhibitors
EP3683618A1 (en) * 2019-01-21 2020-07-22 Essilor International (Compagnie Generale D'optique) System and method for demonstrating an optical disorder
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
US20240269066A1 (en) * 2021-06-08 2024-08-15 Precvision Biotechnologies Ltd. Use of cyp450 inhibitor in inhibiting or killing mites and treating xerophthalmia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095257A2 (en) * 2013-12-18 2015-06-25 Emory University Managing visual dysfunction or loss of vision for diabetic subjects
WO2019195761A2 (en) * 2018-04-05 2019-10-10 Calasia Pharmaceuticals, Inc. Pharmacological agents for treating ocular diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMYLOID, vol. 28, JPN6025049977, 2021, pages 24 - 29, ISSN: 0005745972 *

Also Published As

Publication number Publication date
US20240000812A1 (en) 2024-01-04
EP4243798A4 (en) 2024-08-21
WO2022104383A1 (en) 2022-05-19
MX2023005675A (es) 2023-07-31
CA3202073A1 (en) 2022-05-19
EP4243798A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
US20230293527A1 (en) Treatment of inflammatory disorders
JP2023549533A (ja) 眼の状態を処置するための薬理剤
ES2374336T3 (es) Agente profiláctico o terapéutico para una enfermedad ocular posterior que comprende un agonista selectivo no ergótico del receptor d2 como principio activo.
US11872236B2 (en) Pharmacological agents for treating ocular diseases
CN108601768A (zh) 用于治疗老花眼的组合物
WO2023202705A1 (zh) 一种眼用制剂及其在治疗老花眼中的应用
RU2733432C1 (ru) Лечение вирусного конъюнктивита с применением ранпирназы и/или амфиназы
CN116963727A (zh) 用于治疗眼部病症的药剂
CA2744898A1 (en) Topical formulations of flap inhibitors for administration to an eye
EP3976017A1 (en) Pharmacological agents for treating protein aggregation diseases of the eye
JP6499290B2 (ja) メラニンならびにメラニン類似体、前駆体、および誘導体による眼疾患、眼障害および眼症状の治療および予防のための方法
CN110650740A (zh) 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物
JP2011518828A (ja) 眼球障害の処置のためのpai−1の発現および活性インヒビター
HK40103320A (zh) 用於治疗眼部病症的药剂
WO2022034909A1 (ja) セペタプロストを含有する医薬製剤
WO2023278604A1 (en) Pharmacological agents for treating ophthalmic diseases
TW200904429A (en) Compositions and methods for modulating inflammation using fluoroquinolones
CN114949229A (zh) 一种含有非甾体抗炎药的眼用药物组合物及其制备方法和用途
ES2272771T3 (es) Uso de aminometil cromanos sustituidos en el tratamiento de transtornos extrapirimidales del movimiento.
TW201318628A (zh) 含有黃素腺嘌呤二核苷酸或其塩為有效成分之角膜上皮細胞死亡抑制劑
JP7417531B2 (ja) 選択的syk阻害剤の使用方法および医薬組成物
Sgambellone Histamine H3 receptor (H3R) antagonist-Nitric Oxide (NO) donor hybrid compounds as a new therapeutic strategy for the treatment of glaucoma and retinal neuroprotection
BRPI0714985A2 (pt) inibidores de monoamina oxidase éteis para tratar distérbios da retina externa
JP2010013387A (ja) 血管新生阻害剤
HK40050888A (en) Pharmacological agents for treating ocular diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225